dabrafenib + LTT462 + trametinib

This combination consists of **dabrafenib**, **LTT462**, and **trametinib**—three investigational and/or approved targeted therapies used together, primarily in research settings, for advanced/metastatic cancers harboring BRAF V600 mutations. Dabrafenib is a selective inhibitor of mutant BRAF kinase, trametinib is a selective inhibitor of MEK1/2, and LTT462 is a highly selective ERK1/2 inhibitor. The combination is being tested to overcome resistance mechanisms in the MAPK pathway and achieve more sustained inhibition than dual BRAF-MEK inhibition alone. It is primarily under clinical investigation in advanced/metastatic BRAF V600 colorectal cancer and possibly other solid tumors[5]. Dabrafenib and trametinib are approved drugs, while LTT462 is an investigational agent developed by Novartis.

Other names

dabrafenib + LTT462 + trametinib